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Objectives We examined the efﬁcacy and durability of a new interwoven self-expanding nitinol
stent system in the treatment of complex popliteal artery lesions in unselected patients.
Background The optimal endovascular treatment strategy for atherosclerotic popliteal artery dis-
ease is not known.
Methods We retrospectively analyzed the data gathered in 101 consecutive patients presenting
with atherosclerotic, popliteal arterial disease, who underwent implantation of 125 stents. The pa-
tients were followed for 12 months by Doppler ultrasound examinations, stent roentgenograms, and
estimation of Rutherford-Becker class (RBC) and ankle-brachial index (ABI).
Results The mean age of the patients was 73.1 years, and 52.5% were men. Total occlusions were
present in 48 patients (47.5%). The mean stent length was 84.3  45.1 mm (range 40 to 240 mm). A
30% residual stenosis was achieved in 98.0% of procedures. The 6- and 12-month primary patency
rates were 94.6  2.3% and 87.7  3.7%, respectively, and the secondary patency rates 97.9  1.5%
and 96.5  2.0%, respectively. Between baseline and 12 months of follow-up, mean ABI increased
from 0.58  0.15 to 0.97  0.18, and mean RBC decreased from 3.1  0.9 to 1.4  0.8 (p  0.001
for both comparisons). Radiographs performed on 51 patients, at a mean of 15.2 months, conﬁrmed
the absence of stent fractures in 100% of examinations.
Conclusions Over a 12-month observation period, the patency rate and durability of SUPERA stents
implanted for severe popliteal artery disease were high. (J Am Coll Cardiol Intv 2013;6:65–71) © 2013
by the American College of Cardiology Foundation
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66The recent guidelines formulated in the comprehensive
American College of Cardiology/American Heart Associa-
tion 2005 Practice Guidelines for the Management of
Patients With Peripheral Arterial Disease (1) and the 2007
Inter-Society Consensus for the Management of Peripheral
Arterial Disease (TASC II) (2) favored percutaneous
transluminal angioplasty as the initial preferred option for
endovascular treatment of symptomatic femoropopliteal
arterial lesions, with bail-out stent placement after a subop-
timal or failed result from balloon dilation. More recent
data, however, suggest that particularly for longer lesions of
the superficial femoral artery (SFA), patency rates after
systematic primary stenting are significantly higher than
after balloon dilation and provisional stenting (3). In fact,
recent data from studies on nitinol stent implantation in the
SFA have reported encouraging patency rates of 60% to
80% at 12 months (4–7).
On the basis of the available clinical evidence, implan-
tation of nitinol stents into the SFA has become a widely
used technique overall, resulting in improved clinical
outcome of percutaneous procedures. By contrast, there is
still a relative uncertainty about the role of endovascular
stenting in the popliteal artery.
Because scientific reports have
traditionally combined the pop-
liteal artery with the SFA, there
is little scientific information
available on the outcome of
endovascular techniques in the
popliteal artery. In fact, pa-
tients with isolated popliteal
disease are largely underrepresented in the available
literature.
The popliteal artery, unlike the SFA, has unique charac-
teristics because it embryologically originates from the
sciatic system (8,9). Most important, this arterial segment is
highly exposed to biomechanical forces resulting from
repetitive flexion of the knee (10–12). Concerns have been
expressed that the implantation of stents, particularly in the
popliteal artery, may be complicated by an unacceptable risk
of stent fracture.
Although non–stent-based solutions for the popliteal
artery may seem appealing, very few data are available,
and stenting may still be required in a high percentage of
patients after initial angioplasty procedures (8). We have
recently reported 24-month results in the treatment of
complex SFA lesions, using a novel, highly flexible,
self-expanding interwoven nitinol stent (7). Over the
2-year follow-up, we observed a high patency rate to-
gether with significant clinical improvements. Most im-
portant, no stent fractures were observed over the 24-
Abbreviations
and Acronyms
ABI  ankle-brachial index
RBC  Rutherford-Becker
class
SFA  superficial femoral
arterymonth surveillance period, which suggests that this stentmay also be very suitable for implantation into the
popliteal artery.
The objective of this registry was to evaluate the efficacy
and integrity of this new nitinol stent system in complex
popliteal artery obstructions, implementing a clinically es-
tablished systematic follow-up regime with stent fracture
screening and evaluation for restenosis. To derive both
scientifically and clinically meaningful information, the
registry intentionally allowed enrollment of a wide range of
obstructions, including long lesions, total occlusions, and
highly calcified vessels, without pre-specified inclusion and
exclusion criteria.
Methods
Patient population. The medical records of 101 consecutive
patients who had undergone implantation of SUPERA
stents (IDEV Technologies, Webster, Texas) for the treat-
ment of popliteal artery disease between January 2008 and
April 2010, at Park Hospital, Leipzig, Germany, were
retrospectively reviewed to collect clinical information be-
tween study enrollment and 12 months of follow-up. This
represents about one-third of all popliteal interventions
performed during that period. The decision to implant a
stent was left to the operator’s judgment, although the
general indications after primary percutaneous transluminal
angioplasty were followed, including hemodynamically se-
vere residual stenosis, flow-limiting dissection, or elastic
recoil.
All patients underwent baseline physical examinations
with a focus on manifestations of lower limb ischemia,
classified according to Rutherford et al. (13). Patients were
assessed for the pain-free walking distance while walking
fast. According to our institutional routine, patients were clas-
sified to Rutherford-Becker class 1 (RBC 1) if walking distance
was more than 300 m and to RBC 3 if walking distance was100
m. RBC 2 was determined if the walking distance was between
100 and 300 m. In indecisive situations, a treadmill test was
performed.
The ankle-brachial index (ABI) was measured, and du-
plex ultrasound studies were performed, followed by selec-
tive angiography of the popliteal artery to outline the
vascular anatomy and define the lesion characteristics. In
accordance with the institutional and local regulatory poli-
cies, all patients signed a written informed consent form
before undergoing the procedure.
Inclusion and exclusion criteria. There were no formal in-
clusion or exclusion criteria specified for this analysis other
than a SUPERA stent was implanted into the popliteal
artery to treat symptomatic de novo or restenotic (outside a
previously implanted stent) popliteal artery lesion. Recipi-
ents of other stents were excluded from the analysis. The
popliteal artery segments are defined as follows: P1 segment,
from intercondylar fossa to proximal edge of patella; P2
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67segment, from proximal part of patella to center of knee
joint space; and P3 segment (below knee popliteal artery),
from center of knee joint space to origin of anterior tibial
artery.
Stent procedure and medication regimens. The SUPERA
stent system includes a 7-F coaxial delivery system with the
pre-mounted stent. A detailed description of the system and
of its deployment method has been published previously (7).
Since 2011, the SUPERA stent has had an improved
delivery system. However, in this study, all stents were still
equipped with the first-generation delivery system. All
lesions were pre-dilated, and balloon size was determined by
visual estimation. Stents were not post-dilated, because
further stent expansion cannot be achieved by post-dilation.
Additional devices used were up to the investigators’ dis-
cretion: Rotarex catheters (Straub Medical, Wangs, Swit-
zerland) and thrombolysis were used in lesions with throm-
botic material. The outback device was used if crossing the
lesion was not possible by conventional means. Inflow and
outflow lesions were treated if they were significant. Out-
flow lesions were treated to establish straight-line flow
through at least 1 vessel to the foot.
The antithrombotic regimen was administered according
to the usual institutional practices. Periprocedural anticoag-
ulation with 5,000 U of heparin was recommended. Dual
antiplatelet therapy with ticlopidine or clopidogrel and
aspirin was administered for at least 4 weeks after the
procedure, with the recommendation to continue aspirin
indefinitely.
Follow-up and study endpoints. All patients were evaluated
before their discharge from the hospital, and were scheduled
to return for ambulatory follow-up visits according to our
institutional standards at 6 and 12 months after the index
procedure, at which times they underwent physical exami-
nations, estimates of RBC, ABI measurements, and duplex
ultrasound studies for the detection of restenoses. Not all
patients were willing to return for the follow-up examina-
tions: Duplex ultrasound and clinical assessment were avail-
able for 90 and 72 patients after 6 and 12 months,
respectively. The duplex ultrasound recordings were ana-
lyzed by an investigator who was not involved in the
initial treatment procedure. A peak systolic velocity ratio
2.4 (corresponding to a 50% decrease in vessel
diameter) (14) was used for the diagnosis of binary
restenosis. To confirm the integrity of the stent, plain
roentgenographic images of the stented segment were
obtained. These assessments are part of our routine
follow-up protocol and are typically performed at around
12 months after the index procedure.
The primary efficacy endpoint of this analysis was stent
patency, defined as absence of binary restenosis on duplex
ultrasound examination without repeat target lesion interven-
tions The secondary endpoints included: 1) procedural success,
defined as a 30% residual vessel stenosis; 2) clinical statusaccording to the RBC; 3) ABI measurements; 4) incidence of
stent fractures on radiographic screening; and 5) rate of target
lesion revascularization.
Statistical analysis. Descriptive statistics were used to
resent: 1) mean values and standard deviation (SD) for
ontinuous variables; 2) median values (range); and
) counts and percentages for categorical variables. Cumu-
ative patency rates and standard errors (SE) were estimated,
sing Kaplan-Meier analyses. Between-group comparisons
ere made with the log-rank test. Mean ABI and RBC
ere compared at various time points, using the Student t
est for dependent samples. Statistical significance was
efined as p  0.05. Analyses were performed using SPSS
oftware, version 11 (SPSS, Chicago, Illinois).
esults
The analysis included 53 men (52.5%) and 48 women
(47.5%), whose mean age was 73.1  10.1 years. The
baseline clinical characteristics of these 101 patients are
shown in Table 1. Cardiovascular risk factors were highly
prevalent, including hypertension in 99.0%, current or
former smoking in 40.6%, and diabetes in 49.5% of patients.
Furthermore, 46.5% of patients presented with severe clau-
dication (RBC 3), and 22.8% presented with critical limb
ischemia (RBC 4 to 5). The mean ABI at rest was 0.58 
.15.
Angiographic and procedural characteristics and immediate
results. A total of 125 stents, 4 to 6 mm in diameter and 40
o 150 mm in length, were implanted in the 101 patients,
epresenting a mean stent length of 84.3  45.1 mm (range
0 to 240 mm) implanted in a mean lesion length of 58.4
4.3 mm (range 10 to 200 mm). The angiographic and
rocedural characteristics and the immediate procedural
Table 1. Clinical Characteristics of 101 Patients With
Popliteal Artery Disease
Age, yrs 73.1 10.1
Men 53 (52.5)
Medical history
Smoking 41 (40.6)
Active 22 (21.8)
Previous 19 (18.8)
Diabetes 50 (49.5)
Insulin-dependent 24 (23.8)
Oral medication 26 (25.7)
Hypertension 100 (99.0)
Hyperlipoproteinemia 63 (62.4)
Coronary artery disease 60 (59.4)
Cerebrovascular disease 15 (14.9)
Rutherford-Becker class 3.1 1.0
Ankle-brachial index at rest 0.58 0.15Values are mean SD or n (%) of observations
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68results and complications are shown in Table 2. The degree
of calcification, from mild for 5-mm calcium deposits in
the vessel wall, to moderate for 5-mm deposits, to major
or deposits filling up the entire vessel diameter, was graded
n the basis of the amount of calcium deposits visible during
uoroscopy. Using this classification, more than 50% of the
esions were moderately to severely calcified.
A visually estimated, residual arterial stenosis 30% was
Table 2. Angiographic and Procedural Characteristics in 101 Recipients
of 125 Popliteal Artery Stents
Treated leg
Right 46 (45.5)
Left 55 (54.5)
Stented arterial segment
P1 39 (38.4)
P2 48 (47.5)
P3 14 (13.9)
Total occlusion 48 (47.5)
Stenosis 53 (52.5)
Calciﬁcations
None 20 (19.8)
Mild 29 (28.7)
Moderate 21 (20.8)
Severe 31 (30.7)
Vessel run-off
0 or 1 vessel 41 (40.6)
2 or 3 vessels 60 (59.4)
Lesion length, mm* 58.4 34.3 (10–200)
Stent length, mm 84.3 45.1 (40–240)
Number of stents implanted per patient
1 78 (77.2)
2 22 (21.8)
3 1 (1.0)
Additional procedures
Inﬂow 23 (22.8)
Iliac arteries (all bare-metal stents) 3 (3.0)
Superﬁcial femoral artery 21 (20.8)
Standard balloon angioplasty only 4 (4.0)
Drug-coated balloon angioplasty 2 (2.0)
Bare-metal stents 12 (10.9)
Drug-eluting stents 5 (5.0)
Outﬂow (tibial arteries) 24 (23.8)
Standard balloon angioplasty only 15 (14.9)
Drug-coated balloon angioplasty only 5 (5.0)
Drug-eluting stents 4 (4.0)
Special devices or procedural techniques
Outback 4 (4.0)
Atherectomy 2 (2.0)
Rotarex 3 (3.0)
Lyse 5 (5.0)
Procedural success† 99 (98.0)
Values aremean SD (range), or n (%) of observations. Note: The same patientmay have had1
additional procedures. *Visual assessment. †Estimated post-procedural residual stenosis30%.chieved in 99 patients (98.0%).Patient survival. Between their discharge from the hospital
nd 12 months, 10 patients died. One of these deaths
ccurred in a patient who initially presented with critical
imb ischemia (RBC 5). The patient was readmitted at 6
onths with an acute stent reocclusion. Despite an imme-
iate reintervention, an amputation at the calf became
ecessary, and the patient died about 2 months later. No
ther individuals had minor or major amputations. All other
eaths were unrelated to the vascular disease of the patients.
Stent patency. The rates of primary and secondary stent
patency at 6 and 12 months of follow-up are shown in Table 3.
The primary stent patency rate at 6 and 12 months were
94.6  2.3% and 87.7  3.7%, respectively. Of 10 patients
ho suffered in-stent occlusions (n  4) or in-stent
estenosis (n  6), 7 were successfully recanalized per-
utaneously. The remaining patients were treated conser-
atively. Therefore, the secondary patency rate at 12
onths of follow-up was 96.5  2.0%.
The graphic displays of cumulative rates of primary and
econdary stent patency up to 12 months of follow-up are
hown in Figure 1.
RBC, ABI, and X-ray examinations. The mean RBC de-
creased from 3.1  1.0 before the index stent implantation
procedure, to 1.6  0.9 at 6 months, and 1.4  0.8 at 12
months (Table 4). The ABI increased from 0.58  0.15
before the stent implantation procedure (Table 1),
to 0.93  0.19 at 6 months, and 0.97  0.18 at 12 months
(Table 3). These changes in RBC and ABI from baseline
were highly statistically significant (p  0.001). Follow-up
radiographs of the stents, obtained in 51 patients at a mean
follow-up of 15.2 months, confirmed the absence of stent
fractures in 100% of examinations.
Table 3. Stent Patency Rates, ABI, and Cumulative Numbers of
Adverse Events at 6 and 12 Months of Follow-Up
Baseline
Follow-Up (Months)
6 12
Stent patency, %
Primary — 94.6 2.3 87.7 3.7
Secondary — 97.9 1.5 96.5 2.0
Ankle-brachial index 0.58 0.15 0.93 0.19* 0.97 0.18*
Cumulative adverse events
Death — 5 10
In-stent occlusion — 3 4
50% In-stent restenosis — 3 6
Amputation — 0 1
Repeat percutaneous
recanalization
— 3 7
Values are mean SD (SE for stent patency results), or number of observations. Note: The same
patient may have suffered1 adverse event. *p 0.001.ABI ankle-brachial index.
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69Discussion
Non–stent-based solutions are currently favored as interven-
tional treatment options for lesions affecting the popliteal
arteries. Although dedicated data on the outcome of balloon
angioplasty procedures in the popliteal segment are missing,
reported patency rates after femoropopliteal balloon angio-
plasty are generally not convincing and may be as low as
30% to 40% (6). Alternative therapies, such as atherectomy
procedures, have been applied in selected patients; however,
no systematic reports specific to the use in the popliteal
artery are available. A recently published small study com-
paring directional atherectomy treatment of the popliteal
artery with balloon dilation found a somewhat better acute
outcome after atherectomy procedures as expressed by a
lower need for bail-out stenting. However, follow-up data
after 1 year could not demonstrate a sustained benefit and
showed identical re-obstruction rates as that of balloon
angioplasty (8).
Figure 1. Cumulative Rates of Primary and Secondary Stent Patency up
to 12 Months of Follow-Up
Blue line  primary patency. Green line  secondary patency.
Table 4. RBC Before Intervention and at Follow-Up
RBC Baseline (n  101) 6 MFU (n  90) 12 MFU (n  72)
1 0 (0.0%) 56 (49.5%) 49 (48.5%)
2 31 (30.7%) 19 (14.9%) 16 (15.8%)
3 47 (46.5%) 12 (9.9%) 6 (5.9%)
4 9 (8.9%) 2 (2.0%) 0 (0.0%)
5 14 (13.9%) 1 (1.0%) 1 (1.0%)
6 0 (0.0%) 0 (0.0%) 0 (0.0%)
Mean (SD) 3.1 1.0 1.6 0.9* 1.4 0.8*
Values are n (%), except as noted. *p 0.001.RBC Rutherford-Becker class.The introduction of nitinol stents for treatment of the
SFA has resulted in markedly improved acute and midterm
results, at least for lesions with a length up to around 15 cm
(3–7). For longer lesions, results were less convincing,
and the reported issue of stent fractures with first-
generation nitinol stents raised concerns about the suit-
ability of stenting for those complex lesions (4,15).
Clearly, these observations have also contributed to a
widespread reluctance to implant stents into the popliteal
artery. Indeed, due to its location across the knee joint
and the fact that the artery is not contained in a muscular
compartment, the characteristics of the popliteal artery are
unique (10). Most important, the artery is highly exposed to
mechanical forces and undergoes significant bending and
foreshortening during knee movements (11,12). Due to
their design characteristics, standard nitinol stents are
mostly not suitable to fulfill these mechanical requirements,
and significant stent fractures have been reported in the
literature (16).
The novel SUPERA interwoven self-expanding nitinol
stent (Fig. 2), which has been studied in this analysis,
Figure 2. Bended-Knee X-Ray Image of a SUPERA Stent in the
Popliteal Artery
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70consists of woven nitinol wires braided in a tubular mesh
configuration. The design configuration results in a stent
that is flexible, compliant, and self-expanding and has a
very high radial resistive strength. These features make
the stent more suitable to withstand dynamic forces such
as compression, torsion, bending, shortening, and pulsa-
tion. In a previous analysis of its use in the SFA, the
device has been shown to have very good patency rates
up to 2 years, as well as a complete absence of stent
fractures (7).
In general, these encouraging results obtained in the SFA
have been almost completely reproduced in the current
analysis dedicated to the popliteal artery location. Patency
rates after 1 year were almost identical to the results
obtained with the SUPERA stent in the SFA at the
corresponding time point (87.7% in the popliteal artery vs.
84.7% in the SFA) (7). Moreover, in the popliteal artery, a
complete absence of stent fracture has also been demon-
strated, offering reassurance that this novel stent design is
durable and similarly suited for implantation into the
popliteal artery as well as the SFA.
Although the mean length of the stented segment was
somewhat shorter in the popliteal dataset (84 vs. 111
mm), from a clinical standpoint, patients with obstruc-
tion in the popliteal artery were generally more challeng-
ing compared with the reported SFA cohort. There were
more patients with critical limb ischemia RBC 4 and 5
(22.8% vs. 16.8%), also shown by a lower baseline ABI
(0.58 vs. 0.68). The likely explanation is that due to the
more distal location of the obstruction, patients had
poorer collateralization. In addition, the fact that in- and
outflow interventions were performed in 22.8% and
23.8%, respectively, of the patients shows that multilevel
disease is a typical disease pattern in patients with
popliteal artery obstructions.
Despite these challenging clinical conditions, a good
clinical effect of the treatment has been demonstrated by an
improvement of the mean RBC class from 3.1 at baseline to
1.4 at 1-year follow-up. In fact, the clinical improvement
after popliteal stenting was even higher as compared with
the SFA cohort and was also supported by a greater
improvement of the ABI value (7).
The question of how liberally these novel stents should be
used in the popliteal artery is difficult to answer from this
initial dataset and certainly requires a randomized head-to-
head comparison to other available technologies and treat-
ment strategies, including drug-eluting balloons, which
have been shown to have great potential in other areas of the
femoropopliteal tract (17–19).
Study limitations. Limitations of the presented data include
the retrospective single-arm, single-center design of the
analysis. However, the broad clinical spectrum of included
cases without pre-specified inclusion and exclusion criteria
gives a good “real-world” impression of the performance ofthe novel SUPERA stent in the popliteal location and is the
largest reported cohort to date on stent-based treatment in
this vascular bed. Further evidence, in the form of random-
ized controlled trials, is needed to confirm these first
encouraging results.
Reprint requests and correspondence: Dr. Dierk Scheinert,
Center for Vascular Medicine, Park Hospital Leipzig, Strumpell-
strasse 41, 04289 Leipzig, Germany. E-mail: scheinert@
parkkrankenhaus-leipzig.de.
REFERENCES
1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice
guidelines for the management of patients with peripheral arterial
disease (lower extremity, renal, mesenteric, and abdominal aortic): a
collaborative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovascular An-
giography and Interventions, Society for Vascular Medicine and Biol-
ogy, Society of Interventional Radiology, and the ACC/AHA Task
Force on Practice Guidelines (Writing Committee to Develop Guide-
lines for the Management of Patients With Peripheral Arterial Dis-
ease). J Am Coll Cardiol 2006;47:1239–312.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG, for the TASC II Working Group. Inter-Society Consensus for the
Management of Peripheral Arterial Disease (TASC II). J Vasc Surg
2007;45 Suppl S:S5–67.
3. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus
implantation of nitinol stents in the superficial femoral artery. N Engl
J Med 2006;354:1879–88.
4. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol
stents for the treatment of atherosclerotic lesions in the superficial
femoral artery: long-term results from the SIROCCO trial. J Endovasc
Ther 2006;13:701–10.
5. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation
in long superficial femoral artery lesions: 12-month results of the
DURABILITY I study. J Endovasc Ther 2009;16:261–9.
6. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation
versus balloon angioplasty for lesions in the superficial femoral
artery and proximal popliteal artery: twelve-month results from
the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:
267–76.
7. Scheinert D, Grummt L, Piorkowski M, et al. A novel self-expanding
interwoven nitinol stent for complex femoropopliteal lesions: 24-
month results of the SUPERA SFA registry. J Endovasc Ther
2011;18:745–52.
8. Semaan E, Hamburg N, Nasr W, et al. Endovascular management of
the popliteal artery: comparison of atherectomy and angioplasty. Vasc
Endovascular Surg 2010;44:25–31.
9. Sadler TW. Langman’s Medical Embryology. 10th edition. Philadel-
phia, PA: Lippincott Williams & Wilkins, 2006.
10. Valentine RJ, Wind GG. Anatomic Exposures in Vascular Surgery.
2nd edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2003.
11. Kröger K, Santosa F, Goyen M. Biomechanical incompatibility of
popliteal stent placement. J Endovasc Ther 2004;11:686–94.
12. Hoffmann U, Vetter J, Rainoni L, Leu AJ, Bollinger A. Popliteal artery
compression and force of active plantar flexion in young healthy
volunteers. J Vasc Surg 1997;26:281–7.
13. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for
reports dealing with lower extremity ischemia: revised version. J Vasc
Surg 1997;26:517–38.
14. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral
arteries: correlation of the peak velocity ratio with angiographic
diameter reduction. Ultrasound Med Biol 1992;18:433–40.
15. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of
stent fractures after femoropopliteal stenting. J Am Coll Cardiol
2005;45:312–5.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 , 2 0 1 3 Scheinert et al.
J A N U A R Y 2 0 1 3 : 6 5 – 7 1 Results of the Popliteal SUPERA Registry at 12 Months
7116. Chang IS, Chee HK, Park SW, et al. The primary patency and fracture
rates of self-expandable nitinol stents placed in the popliteal arteries,
especially in the P2 and P3 segments, in Korean patients. Korean J
Radiol 2011;12:203–9.
17. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to
inhibit restenosis during angioplasty of the leg. N Engl J Med
2008;358:689–99.
18. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in
femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral
paclitaxel randomized pilot trial. Circulation 2008;118:1358–65.19. Micari M, Cioppa A, Vadalà G, et al. Clinical evaluation of a
paclitaxel-eluting balloon for treatment of femoropopliteal arterial
disease: 12-month results from a multicenter Italian registry. J Am Coll
Cardiol Intv 2012;5:331–8.
Key words: nitinol stent  peripheral artery disease 
popliteal artery disease  popliteal artery stenting  stent
fracture.
